HB7837, the "Most Favored Patient Act of 2026," would require the Center for Medicare and Medicaid Innovation (CMMI) to test a new drug-pricing model beginning January 1, 2029. The model would apply to certain prescription drugs, Medicare Part B drugs and biologics, and Part D drugs, and would require participating manufacturers to give eligible Medicare and Medicaid beneficiaries access to a "most-favored-nation" price. That price is defined as the second-lowest net price paid in a set of reference countries, after accounting for rebates, discounts, concessions, and purchasing-power adjustments.
The bill also requires manufacturers to report pricing information needed to calculate the most-favored-nation price. It allows the Secretary of Health and Human Services to suspend the pricing requirement for a drug until April 1, 2029 if the manufacturer is likely to enter into a covered agreement before then. A covered agreement would let a manufacturer avoid the test model if it agrees to provide the same pricing access, report the required information, and commit to increasing manufacturing operations in the United States. The model would run for five years.
In practical terms, the bill would amend section 1115A of the Social Security Act and expand CMMI’s mandatory testing authority to include this drug-pricing demonstration. It would affect drug manufacturers, pharmacies, mail-order services, hospitals, physicians, other providers, and Medicare and Medicaid beneficiaries who receive covered drugs. It also creates new statutory definitions for covered drugs, reference countries, eligible individuals, and most-favored-nation pricing, while tying the policy to Medicare Part B, Medicare Part D, and Medicaid coverage rules.
The overall sentiment in the available record appears supportive of lowering prescription drug costs, but there is no committee transcript or vote history provided to show detailed debate or bipartisan support/opposition. Because the bill has only been referred to committee, it has not yet advanced to a recorded vote. The structure of the bill suggests a policy emphasis on consumer savings and domestic manufacturing incentives, which may appeal to supporters of drug-price reform while raising concerns among manufacturers about pricing controls and administrative burden.
The main point of contention is likely the use of international reference pricing and the requirement that manufacturers offer U.S. patients the second-lowest net price from selected foreign markets. Drug manufacturers may object to the effect on revenues, the disclosure requirements, and the possibility that the model could pressure prices across markets. Supporters are likely to emphasize affordability for Medicare and Medicaid patients and the incentive for manufacturers to negotiate agreements that preserve access while expanding U.S. production.
The bill would amend section 1115A of the Social Security Act to direct CMMI to test a mandatory Most Favored Nations Pricing Model starting in 2029. It would create new federal requirements for certain drug manufacturers to provide eligible Medicare and Medicaid beneficiaries access to a benchmark price based on the second-lowest net price in specified foreign countries, and to report pricing data to HHS. The bill would also establish a pathway for manufacturers to enter covered agreements in exchange for compliance relief and a commitment to increase U.S. manufacturing.
The available context suggests the bill is intended as a drug-pricing reform measure aimed at reducing prescription drug costs for Medicare and Medicaid patients. No committee discussion or votes are available, so there is no recorded legislative debate to measure support or opposition. Based on the text alone, the bill appears designed to appeal to supporters of aggressive price controls and domestic manufacturing incentives, while likely drawing resistance from pharmaceutical manufacturers and others concerned about pricing regulation.
The most likely controversy is over the most-favored-nation pricing mechanism itself, which ties U.S. prices to foreign reference-country prices and could significantly reduce manufacturer revenue. Manufacturers may also object to the reporting obligations and the requirement to disclose pricing information needed to calculate the benchmark. Another point of tension is the bill’s incentive structure: it offers a way to avoid the model through a covered agreement, but only if the manufacturer agrees to provide the same pricing access and increase U.S. manufacturing, which may be viewed as coercive or administratively burdensome.